VEGFA and neoplasm: Oral administration of Vandetanib (ZD6474), an FDA approved small molecule tyrosine kinase inhibitor of VEGFR222, has been demonstrated to inhibit tumor angiogenesis by decreasing endothelial cell proliferation and VEGF-dependent endothelial cell survival23.